Viridian Therapeutics Bolsa (NASDAQ: VRDN)

Viridian Therapeutics (NASDAQ:VRDN) Bolsa

VIRIDIAN THERAPEUTICS INC

Viridian Therapeutics

Viridian Therapeutics Inc is a clinical-stage biopharmaceutical company that engages in developing multiple product candidates to treat patients who suffer from thyroid eye disease. Its product candidate includes Veligrotug (formerly known as VRDN-001) for intravenous (IV) and VRDN-003 for subcutaneous (SC) administration. Veligrotug is a differentiated humanized monoclonal antibody targeting IGF-1R intravenously administered for the treatment of thyroid eye disease (TED).

Viridian Therapeutics, Inc. - Common Stock

Viridian Therapeutics Inc

<a href="https://www.bloomberg.com/news/articles/2025-05-12/amc-to-slash-movie-ticket-prices-by-50-on-wednesdays?embedded-checkout=true">https://www.bloomberg.com/news/articles/2025-05-12/amc-to-slash-movie-ticket-prices-by-50-on-wednesdays?embedded-checkout=true</a>

News

General

'AMC to Slash Movie Ticket Prices by 50% on Wednesdays'- Bloomberg

Barclays analyst Julian Mitchell maintains Kennametal (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KMT#NYSE">KMT</a>) with a Equal-Weight and raises the price target from $22 to $24.

Price Target

Analyst Ratings

Barclays Maintains Equal-Weight on Kennametal, Raises Price Target to $24

Guidance

BSLK

Bolt Projects Holdings Sees FY2026 Revenue To Be At Least $9M

Microvast Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MVST#NASDAQ">MVST</a>) affirms FY2025 sales outlook from $450.00 million-$475.00 million to $450.00 million-$475.00 million vs $462.97 million estimate.

MVST

Microvast Holdings Affirms FY2025 Sales Guidance of $450.00M-$475.00M vs $462.97M Est

Bolt Projects Holdings Sees FY2025 Revenue Of Atleast $4.5M

Copart (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CPRT#NASDAQ">CPRT</a>) has outperformed the market over the past 15 years by 12.98% on an annualized basis producing an average annual return of 24.58%. Currently, Copart has a market capitalization of $60.14 billion. 
Buying $100 In CPRT: If an investor had bought $100 of CPRT stock 15 years ago, it would be worth $2,674.99 today based on a price of $62.25 for CPRT at the time of writing.
<h3>Copart's Performance Over Last 15 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1747084514_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Trading Ideas

CPRT

If You Invested $100 In This Stock 15 Years Ago, You Would Have This Much Today

Village Farms International Announces Transformative Transaction to Privatize Its Fresh Produce Business; Village Farms' Fresh Segment To Become Cornerstone Of Newco's Commercial Operations And Growth Strategy; Expects To Receive $40M In Cash Proceeds; 37.9% Equity Ownership Interest In Newco; Retains Ownership Of All Canadian Cultivation Assets

Bolt Projects Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BSLK#NASDAQ">BSLK</a>) reported quarterly losses of $(3.00) per share. This is a 89.37 percent increase over losses of $(28.22) per share from the same period last year. The company reported $171.00 thousand in sales this quarter. This is a 800.00 percent increase over sales of $19.00 thousand the same period last year.

Earnings

Bolt Projects Holdings Q1 EPS $(3.00) Up From $(28.22) YoY, Sales $171.00K Up From $19.00K YoY

Central Puerto (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CEPU#NYSE">CEPU</a>) reported quarterly earnings of $0.50 per share. This is a 150 percent increase over earnings of $0.20 per share from the same period last year. The company reported $196.00 million in sales this quarter. This is a 130.67M percent increase over sales of $150.00 the same period last year.

CEPU

Central Puerto Q1 EPS $0.50 Up From $0.20 YoY, Sales $196.00M Up From $150.00 YoY

Barclays analyst Adrienne Yih maintains Victoria's Secret (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VSCO#NYSE">VSCO</a>) with a Overweight and lowers the price target from $38 to $23.

VSCO

Barclays Maintains Overweight on Victoria's Secret, Lowers Price Target to $23

Legacy Housing (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LEGH#NASDAQ">LEGH</a>) reported quarterly earnings of $0.43 per share which missed the analyst consensus estimate of $0.57 by 24.56 percent. This is a 28.33 percent decrease over earnings of $0.60 per share from the same period last year. The company reported quarterly sales of $35.70 million which missed the analyst consensus estimate of $43.13 million by 17.23 percent. This is a 17.44 percent decrease over sales of $43.24 million the same period last year.

Earnings Misses

LEGH

Legacy Housing Q1 EPS $0.43 Misses $0.57 Estimate, Sales $35.70M Miss $43.13M Estimate

LSEAW

Trading Halt: Halted at 5:12:38 p.m. ET - Trading Halt: Halt News Pending

LSEA

EVI Industries (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/EVI#AMEX">EVI</a>) reported quarterly earnings of $0.07 per share. This is a 16.67 percent increase over earnings of $0.06 per share from the same period last year. The company reported $93.54 million in sales this quarter. This is a 11.38 percent increase over sales of $83.98 million the same period last year.

EVI Industries Q3 EPS $0.07 Up From $0.06 YoY, Sales $93.54M Up From $83.98M YoY

Barclays analyst Adrienne Yih maintains VF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VFC#NYSE">VFC</a>) with a Overweight and lowers the price target from $34 to $19.

Barclays Maintains Overweight on VF, Lowers Price Target to $19

Tecogen (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/TGEN#AMEX">TGEN</a>) reported quarterly losses of $(0.03) per share. This is a 25 percent increase over losses of $(0.04) per share from the same period last year. The company reported $7.28 million in sales this quarter. This is a 17.65 percent increase over sales of $6.19 million the same period last year.

TGEN

Tecogen Q1 EPS $(0.03) Up From $(0.04) YoY, Sales $7.28M Up From $6.19M YoY

Barclays analyst Adrienne Yih maintains Urban Outfitters (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/URBN#NASDAQ">URBN</a>) with a Overweight and lowers the price target from $68 to $59.

URBN

Barclays Maintains Overweight on Urban Outfitters, Lowers Price Target to $59

DRI HEALTHCARE TRUST Q1 Adj. EPS $0.43 Misses $0.51 Estimate, Sales $44.03M Miss $44.12M Estimate

Barnwell Industries, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BRN#NYSE">BRN</a>) ("Barnwell" or the "Company") today urged shareholders to follow the recommendation by leading proxy advisory firm Institutional Shareholder Services Inc. ("ISS") in its May 7, 2025, report in which it recommended just one candidate, Heather Isidoro, from the slate put forward by Ned Sherwood and his affiliates (the "Sherwood Group").

Management

Barnwell Industries Urges Shareholders To Vote In Accordance With ISS Recommendation And Reject Ned Sherwood's Attempt To Take Over the Company

WhiteHorse Finance (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WHF#NASDAQ">WHF</a>) reported quarterly earnings of $0.29 per share which missed the analyst consensus estimate of $0.34 by 13.53 percent. This is a 36.77 percent decrease over earnings of $0.47 per share from the same period last year. The company reported quarterly sales of $18.80 million which missed the analyst consensus estimate of $20.43 million by 7.96 percent. This is a 26.20 percent decrease over sales of $25.48 million the same period last year.

Comments

Viridian Therapeutics

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL